Introduction
Tumors develop in hosts endowed with a highly complex immune system that includes various lymphocyte subsets capable of recognizing and destroying transformed cells. It is now widely accepted that, although lymphocytes may constantly patrol tumor formation, cancer cells develop molecular strategies to evade immune surveillance, which are competitively selected under the pressure of the host immune system. 1 This dynamic process, termed "cancer immunoediting," is thought to constitute a major obstacle to cancer immunotherapy. 1 Among multiple immune evasion mechanisms, we have recently shown that leukemia and lymphoma primary cells often down-regulate the nonclassical MHC protein, ULBP1, which is critical for recognition of hematologic tumors by ␥␦ T cells expressing the counter-receptor NKG2D. 2 ␥␦ T cells are innate-like lymphocytes that account for 1%-10% of peripheral blood lymphocytes (PBL) of healthy people and are capable of targeting a significant fraction of hematologic tumor cell lines tested in the laboratory. 3 However, we have demonstrated that many lymphoid leukemia cells are resistant to fully activated V␥9V␦2 T cells, 2, 3 the dominant subset of ␥␦ PBLs. Furthermore, clinical trials involving the in vivo administration of activators of V␥9V␦2 T cells have shown limited success, with objective responses restricted to 10%-33% of patients with either hematologic or solid tumors. [4] [5] [6] Even more modest has been the outcome of trials involving the adoptive transfer of activated and expanded V␦2 ϩ cells, because no objective responses have been reported. 6 In fact, the simple ex vivo expansion of autologous V␦2 ϩ T cells, whose surveillance the tumor managed to escape in vivo, may be condemned to little therapeutic effect on reinjection into the patient. Therefore, we believe it is critical to invest in strategies that endow ␥␦ T cells with additional recognition machinery to detect tumors that have resisted the natural components present in vivo.
Besides V␥9V␦2 T cells, V␦1 ϩ T cells are also endowed with potent antitumor cytolytic function, particularly as tissueassociated or tumor-infiltrating lymphocytes. [7] [8] [9] [10] Moreover, V␦1 ϩ T cells can constitute up to 30% of all ␥␦ PBLs and may thus represent an important alternative population for adoptive cell therapy. However, this possibility remains poorly explored.
In this study we identified and characterized a novel V␦1 ϩ PBL subset capable of targeting hematologic tumors highly resistant to fully activated V␥9V␦2 PBLs. We show that this V␦1 ϩ population owes its specialized killer function to induced expression of natural cytotoxicity receptors (NCRs), which have been mostly regarded as NK-specific markers. Instead, we show that, although neither V␦1 ϩ nor V␦2 ϩ cells express NCRs constitutively, these can be selectively up-regulated in V␦1 ϩ cells by AKT-dependent signals provided synergistically by ␥ c cytokines (IL-2 or IL-15) and TCR stimulation. We further show that NKp30 and NKp44 are both functional in NCR ϩ V␦1 ϩ PBLs, and synergistically contribute to enhanced targeting of lymphocytic leukemia cells, with NKp30 playing the major role in this process. Thus, NKp30 ϩ V␦1 ϩ PBL The online version of this article contains a data supplement.
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Methods

Ethics statement
Research involving clinical samples was conducted according to the principles expressed in the Helsinki Declaration. All procedures were approved by the review board of Instituto Português de Oncologia de Lisboa (Portugal).
Isolation of human peripheral blood ␥␦ T cells
Peripheral blood was collected from anonymous healthy volunteers, diluted in a 1:1 ratio (volume-to-volume) with PBS (Invitrogen Gibco), and centrifuged in Ficol-Paque (Histopaque-1077; Sigma-Aldrich) in a volume ratio of 1:3 (1 part ficol to 3 parts diluted blood) for 30 minutes at 1 500 rpm and 25°C. The interfase containing mononuclear cells was collected and washed (in PBS), and ␥␦ T cells were isolated (to above 95% purity) by magnetic cell sorting via positive selection (with a FITC-labeled anti-TCR␥␦ antibody) or via negative selection (with a cocktail of Biotinlabeled antibodies; Miltenyi Biotec). When noted, V␦1 ϩ cells were further purified by magnetic cell sorting via positive selection with a FITC-labeled anti-V␦1 TCR antibody (Fisher Scientific) and anti-FITC microbeads (Miltenyi Biotec).
Cell culture
Isolated ␥␦ PBLs were cultured at 10 6 cells/mL at 37°C, 5% CO 2 in round-bottom 96 well plates with RPMI 1640 and 2 mM l-glutamine (Invitrogen Gibco) supplemented with 10% FBS (Invitrogen Gibco), 1 mM sodium pyruvate (Invitrogen Gibco), and 50 mg/mL of penicillin and streptomycin (Invitrogen Gibco). The cells were expanded in the presence of 100 U/mL of rhIL-2 (Roche Applied Science), with or without 10 nM of HMB-PP (4-hydroxy-3-methyl-but-2-enyl pyrophosphate; Echelon Biosciences) and 1g/mL of phytohemagglutinin (PHA; Sigma-Aldrich). Cells were washed and the culture medium was replaced every 5-6 days. To study the induction of NKp30 expression, ␥␦ PBLs were cultured in the presence or absence of 100 U/mL of rhIL-2 (Roche Applied Science), 1g/mL of soluble anti-CD3 antibody (eBioscience; clone OKT3), and 20ng/mL of rhIL-15 (Biolegend). For TCR blockade, freshly isolated ␥␦ PBL were CFSE-labeled and then incubated for 7 days with anti-TCR␥␦ (Beckman Coulter; clone IMMU510) diluted 1:20 in complete medium supplemented with 1g/mL PHA and 100 U/mL rhIL-2. To study the effects of chemical inhibitors of signal transduction, the MEK inhibitor UO126 and the PI-3K inhibitor LY294002 (both from Calbiochem) were added at 10 mM for a 2-hour incubation period and then maintained in culture with 100 U/mL rhIL-2 and 1g/mL PHA for 7 days.
Flow cytometric cell sorting
For sorting of ␥␦ PBL based on the expression of NKp30 and V␦1 ϩ TCR, cells from PHA and IL-2-activated cultures were stained with anti-NKp30 (Biolegend; clone P30-15), anti-V␦1 (Thermo Fisher Scientific; clone TS8.2), and sorted on a FACSAria cell sorter (BD Biosciences).
Leukemia patient samples
B-cell chronic lymphocytic leukemia cells were obtained from the peripheral blood of patients at presentation, after informed consent and institutional review board approval (Instituto Português de Oncologia de Lisboa, Portugal). Samples were enriched by density centrifugation over FicolPaque and then washed twice in 10% RPMI 1640.
In vitro tumor-killing assays
All tumor cell lines (details provided in supplemental Table 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article) were cultured in complete 10% RPMI 1640, maintained at 10 5 up to 10 6 cells/mL by dilution and splitting in a 1:3 ratio every 3-4 days. For cytotoxicity assays, magnetically purified ␥␦ PBL were preactivated for 7-19 days in the presence of IL-2 (100 U/mL) and either 1g/mL PHA or 10 nM HMB-PP. For receptor blocking, ␥␦ PBLs were incubated for 2 hours with the blocking antibodies anti-NKp30 (clone F252), anti-NKp44 (clone KS38), anti-NKp46 (clone KL247), anti-TCR␥␦ (Beckman Coulter, clones IMMU510 or B1.1), or anti-V␦1 TCR (Fisher Scientific, clones TCS1 or TS8.2). The blocking antibodies were maintained in the culture medium during the killing assays. Tumor cell lines or leukemia primary samples were stained with CellTrace Far Red DDAO-SE (1 M; Molecular Probes, Invitrogen) and each batch of 3 ϫ 10 4 tumor cells was incubated with 1.5 ϫ 10 5 to 3 ϫ 10 5 ␥␦ T cells in RPMI for 3 hours at 37°C and 5% CO 2 on a round-bottom plate with 96 wells. Cells were then stained with annexin V-FITC (BD Biosciences) and analyzed by flow cytometry. For the redirected killing assays, PHA and IL-2-activated ␥␦ PBL were incubated for 4 hours with the NCR agonists anti-NKp30 (clone AZ20), anti-Nkp44 (clone Z231) or anti-NKp46 (clone Bab281) during a standard 51 Cr release assay. 
Flow cytometry analysis
RNA isolation and cDNA production
Total RNA was extracted using the RNeasy Mini Kit according to the manufacturer's protocol (QIAGEN). Concentration and purity was determined by spectrophotometry and integrity was confirmed using an Agilent 2100 Bioanalyzer with a RNA 6000 Nano Assay (Agilent Technologies). Total RNA was reverse-transcribed into cDNA using random hexamers and Superscript II first strand synthesis reagents (Invitrogen).
Real-time quantitative PCR
Real-time quantitative PCR (qPCR) was performed on ABI Prism 7500 FAST Sequence Detection System using SYBR Green detection system (both from Applied Biosystems). Primers were designed using Primer3 v.0.4.0 online program (http://primer3.sourceforge.net). For each transcript, quantification was done using the calibration curve method. ␤ 2 -microglobulin (B2M), Glucoronidase ␤ (GUSB) and proteasome subunit ␤ type 6 (PSMB6) were used as housekeeping controls for normalization of gene expression. The following primers were used: B2M, forward CTAT CCAG CGTA CTCC AAAG ATTC, reverse CTTG CTGA AAGA CAAG TCTG AATG; PSMB6, forward GGCG GCTA CCTT ACTA GCTG, reverse AAAC TGCA CGGC CATG ATA; GUSB, forward TGCA GCGG TGTA CTTC TG, reverse CCTT GACA GAGA TCTG GTAA TCA; B7H6, forward TCAC CAAG AGGC ATTC CGAC CT, reverse ACCA CCTC ACAT CGGT ACTC TC; NKP44, forward CCGT CAGA TTCT ATCT GGTG GT, reverse CACA CAGC TCTG GGTC TGG; NKP46, forward AAGA CCCC ACCT TTCC TGA, reverse TGCT GGCT CGCT CTCT AGT; GZMB, forward GGGG GACC CAGA GATT AAAA, reverse CCAT TGTT TCGT CCAT AGGA G. All samples were run in triplicate and repeated 3 times. Analysis of the qPCR results was performed using the ABI SDS v1.1 sequence analysis software (Applied Biosystems).
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Results
Enhanced cytotoxicity of ␥␦ PBL cultures activated with pan-T-cell mitogen
We compared the antitumor killing capacity of ␥␦ PBL cultures (always maintained in the presence of IL-2) activated either with PHA, a plant lectin that acts as a potent T-cell mitogen, 11 or the specific V␥9V␦2 TCR agonist HMB-PP. 12, 13 Although both regimens were similarly efficient at activating ␥␦ PBLs, as evaluated by CD69 up-regulation and cell proliferation ( Figure 1A ), we noted that samples activated with PHA were consistently better killers of hematopoietic tumor cell lines than samples (of the same donor origin) stimulated with HMB-PP ( Figure 1B-C) . This was valid across all donors tested (Figure 1B, supplemental Table 2 , and data not shown) and was associated with higher expression of GZMB ( Figure 1D ), a key component of the lymphocyte cytolytic machinery. Of note, freshly isolated ␥␦ PBLs, which lack GZMB expression ( Figure 1D ), displayed very poor antileukemia cytotoxicity (Ͻ 10% killing; not shown), as previously reported. 13 
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The superior cytotoxic function of PHA-stimulated ␥␦ PBL cultures was a surprising finding, because we and others have shown that HMB-PP is a very potent activator of the highly dominant V␥9V␦2 PBL subset. 13 We were particularly interested that, compared with HMB-PP-activated ␥␦ PBL, PHA-stimulated cultures displayed improved cytotoxicity against various resistant leukemia cell lines, such as Bv-173, REH or HPB-ALL ( Figure  1B -C), which we had shown to lack expression of the critical NKG2D ligand ULBP1. 2, 3 Of note, PHA-stimulated ␥␦ T cells did not target normal (healthy) PBMC (supplemental Figure 1 ). These data demonstrate that the pan-T-cell mitogen PHA is capable of increasing the cytolytic potential of medium-term (1-3 weeks) ␥␦ PBL cultures against leukemia cells, which could be of great value for adoptive cell immunotherapy.
Induction of NCR expression on ␥␦ PBLs activated with pan-T-cell mitogen
We next investigated the mechanism(s) underlying the enhanced cytotoxicity of PHA-activated ␥␦ PBL cultures. We considered that this could be explained by differential expression of receptors such as NKG2D, 2,14,15 DNAM-1, 16, 17 or 2B4, 18 all previously shown to participate in tumor cell recognition by killer lymphocytes. However, none of these candidates was differentially expressed between PHA-activated and HMB-PP-activated ␥␦ PBL cultures ( Figure  2A ). By contrast, and unexpectedly, the natural cytotoxicity receptor NKp30, an important trigger of NK cell cytotoxicity, 19 was specifically found on PHA-stimulated ␥␦ PBLs ( Figure 2B ; supplemental Figure 2A-B) . Furthermore, the other NCR family members, NKp44 and NKp46, were also selectively expressed in these samples (Figure 2C-D Considering that HMB-PP had been shown to be an optimal agonist of V␥9V␦2 cells, 12, 13 we hypothesized that our findings derived from PHA-mediated activation of a distinct ␥␦ PBL subset. Consistent with this, we observed that, by contrast with HMB-PP, treatment with PHA preferentially expanded V␦2 Ϫ cells among ␥␦ PBL ( Figure 3A) . We verified that this was not because of differences in V␦2 ϩ cell apoptosis in the 2 experimental conditions (supplemental Figure 2C) . The most likely V␦2 Ϫ population to expand so markedly ( Figure 3A) were V␦1 ϩ cells, because other subsets are very rare in the peripheral blood of healthy adults. 20 When V␦1 versus V␦2 TCR usage was assessed, a dramatic V␦1 ϩ cell enrichment was found in PHA-activated cultures (Ͼ 80% of all ␥␦ T cells after 19 days; Figure 3B ; supplemental Figure 4) . LEUKEMIA
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Conversely, and as described, 13 HMB-PP-activated cultures were progressively dominated by V␦2 ϩ cells ( Figure 3A ; supplemental Figure 4 ).
The induction of NKp30 expression was examined in parallel cultures of isolated V␦1 ϩ or V␦2 ϩ cells, which were stimulated with PHA and IL-2. Although neither freshly isolated V␦1 ϩ nor V␦2 ϩ cells expressed NKp30 (supplemental Figure 2B) , this NCR was strongly induced (on PHA and IL-2 treatment) in V␦1 ϩ but not V␦2 ϩ cells ( Figure 3C) . Moreover, by following CFSE dilution, we demonstrated a striking accumulation of NKp30 ϩ cells with progressive division of V␦1 ϩ cells ( Figure 3C ). These data suggest that activation of V␦1 ϩ cells in PHA and IL-2 cultures induces NKp30 expression concomitantly with cell proliferation.
Whereas high percentages (Ͼ 50%) of NKp30 ϩ cells were usually detected after 2 to 3 weeks in culture, NKp44 (ϳ 30%) and NKp46 (Ͻ 20%) were expressed in lower proportions of V␦1 ϩ cells ( Figure 3D ). Furthermore, most of NKp44 ϩ or NKp46 ϩ V␦1 ϩ cells also expressed NKp30 ( Figure 3D ). We therefore considered NKp30 as the most informative marker of the inducible NCR ϩ V␦1 ϩ subset, and we set out to further characterize its differentiation.
NKp30 induction requires AKT-dependent ␥ c cytokine and TCR signals
We next dissected the specific signals required for the differentiation of NCR ϩ V␦1 ϩ T cells. First, the 2 components of the activation protocol, IL-2 and PHA, were dissociated. IL-2, or its related ␥ c cytokine, IL-15, alone were sufficient to induce some NKp30 expression, but the effect was modest compared with PHA and IL-2 (or PHA and IL-15) combinations ( Figure 4A and not shown). On the other hand, PHA alone was not able to keep the cultures viable (data not shown), consistent with the critical role of ␥ c cytokines in the survival of ␥␦ T cells, particularly on activation and proliferation. 13, 21 Although PHA has been a widely used T cell mitogen, it is also a nonphysiologic compound capable of cross-linking a series of surface receptors, including the TCR. 22 We hypothesized that the molecular mediator of PHA stimulation could be the V␦1 ϩ TCR complex. We therefore compared the ability of PHA and the OKT3 mAb, which specifically cross-links CD3⑀ chains of the TCR complex, to induce NKp30 expression (when combined with IL-2 or IL-15) in V␦1 ϩ T cells. OKT3 was fully capable of mimicking PHA in these assays ( Figure 4A-B) , thus inducing NKp30 in proliferating V␦1 ϩ T cells (supplemental Figure 5) . Moreover, TCR␥␦ blockade in PHA and IL-2 cultures prevented NKp30 induction ( Figure 4C ). These data suggest that PHA treatment provides TCR signals to induce NCR expression on V␦1 ϩ PBL. Moreover, the differences between cytokine alone or combination treatments with OKT3 (or PHA) highlight a marked synergy between ␥ c cytokine and TCR signals in this process ( Figure 4A-B) . Figure 4D ). AKT is involved in transducing both ␥ c cytokine and TCR signals, 23 including TCR␥␦ signals. 13 By contrast, the MAPK/Erk inhibitor UO126 had no detectable effect on NKp30 induction in proliferating V␦1 ϩ T cells ( Figure 4D ). Importantly, the selective effect of LY294002 dissociated NCR induction from cell proliferation, thus demonstrating that V␦1 ϩ T-cell proliferation is necessary ( Figure  3C ; supplemental Figure 5 ) but not sufficient ( Figure 4D ) to induce NKp30 expression. Collectively, these data demonstrate that AKTdependent ␥ c cytokine and TCR signals synergize to induce NKp30 expression in V␦1 ϩ T cells.
Functional NKp30 and NKp44 trigger tumor cell killing by V␦1 ؉ PBLs
Although the previous data established clear associations between NKp30 expression and increased cytotoxicity of ␥␦ (V␦1 ϩ ) PBL cultures, the functional role of NCRs in this system remained to be formally demonstrated. We therefore undertook gain-of function and loss-of-function experiments to evaluate the effect of NCR modulation on V␦1 ϩ enriched (Ͼ 80%; supplemental Figure 3A ) PBL cultures, which expressed NCRs at levels similar to those in Figure 3D (not shown). First, using a reverse Ab-dependent cytotoxicity assay, we showed that cross-linking of NKp30 or NKp44, but not NKp46, produced significant increases in lysis of the P815 tumor cell targets ( Figure 5A ). These data demonstrate that induced NKp30 and NKp44 are functional and mediate tumor cell killing. To assess if they played nonredundant roles in targeting leukemia cells, we performed receptor blockade experiments using NCR-specific mAbs (kindly provided by Dr A. Moretta, University of Genova, Italy). We observed significant reductions in tumor cell lysis on NKp30 and NKp44 blockade ( Figure 5B ). As expected from the results in Figure 5A , NKp46 blockade did not affect tumor cell killing. Interestingly, a synergistic effect between NKp30 and NKp44 was also clearly observed. Of note, TCR␥␦ blockade in any setting (alone or in combination with anti-NCR mAbs) was a neutral event during the killing assay ( Figure 5B ). To further establish the TCR-independence of NCR ϩ V␦1 ϩ PBL cytotoxicity, we isolated PHA-activated V␦1 ϩ cells to very high purity (supplemental Figure 6 ) and used 3 different well-described anti-TCR blocking antibodies, including one (TCS1) specific for the V␦1 ϩ TCR. Again, we observed no effect on leukemia cell killing ( Figure  5C ). By contrast, inhibition of NKG2D had a significant ( Figure  5C ) and dose-dependent (supplemental Figure 6C) impact on tumor lysis. In fact, when we combined NCR and NKG2D inhibition, NCR ϩ V␦1 ϩ PBLs could not kill above background levels ( Figure 5C ). These data suggest that leukemia cell targeting by NCR ϩ V␦1 ϩ PBLs is a TCR-independent event mostly mediated by the synergistic function of NKp30, NKp44 and NKG2D. To fully characterize the antitumor potential of NCR ϩ V␦1 ϩ PBL, we used FACS to sort NKp30 ϩ cells to a high degree of purity (Ͼ 99%; Figure 6A ) and performed a series of functional assays. As expected (Figure 3D ), sorted NKp30 ϩ cells also expressed NKp44 and NKp46 ( Figure 6B ), and the 3 NCRs were largely stable on the surface of the purified cells when cultured for 2 weeks with IL-2 alone ( Figure 6C ). These data demonstrate the feasible expansion of a stable NCR ϩ V␦1 ϩ T cell subset.
When the cytotoxic function of NKp30 ϩ cells was assessed, an increased targeting of the resistant leukemia cell line Bv173 (among others; not shown) was observed (in comparison with NKp30 Ϫ counterparts; Figure 6D ). This correlated with higher expression of granzyme B ( Figure 6E ). Moreover, NKp30 expression also associated with higher degree of CD56 expression (supplemental Figure 7) , which has been previously linked to cytotoxicity of human lymphocytes, including V␦2 ϩ T cells 24 ).
Finally, we performed functional killing assays with primary samples obtained from B-cell chronic lymphocytic leukemia patients. We previously showed that such specimens are considerably resistant to ␥␦ PBL activated and expanded with the specific V␥9V␦2 TCR agonist HMB-PP, 3 a finding confirmed in this study ( Figure 6F-G) . Importantly, HMB-PP and IL-2-activated ␥␦ PBLs do not express NCRs ( Figure 2B ). We therefore compared their antitumor cytolytic activity with that of NKp30 ϩ cells isolated from ␥␦ PBL cultures activated with PHA and IL-2. We observed 
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␥␦ PBLs, obtained from 6 different donors, were consistently more efficient at eliminating primary B-CLL cells ( Figure 6F-G) . These data collectively suggest that highly cytotoxic NKp30 ϩ V␦1 ϩ PBL are promising new candidates for adoptive cell immunotherapy of hematologic malignancies.
Discussion
Natural cytotoxicity receptors were identified by A. Moretta and colleagues over a decade ago, and were shown to play critical synergistic roles in the antitumor functions of NK cells. 19, [25] [26] [27] In fact, NKp30 and NKp46 are widely considered to be 2 of the most specific NK markers 19, [25] [26] [27] We now show that the combination of cytokine (IL-2 or IL-15) and mitogenic (PHA or OKT3) stimuli induces NCR expression in a sizeable V␦1 ϩ PBL subset that is endowed with increased cytolytic activity against hematologic tumors. Although PHA is a nonphysiologic T-cell mitogen, we demonstrated that its effect on NCR induction was fully mimicked by crosslinking the TCR-CD3 complex on V␦1 ϩ PBL. Thus, NCR induction is coupled to TCR-mediated proliferation of V␦1 ϩ cells, while also requiring ␥ c cytokine signals. This is consistent with previous reports demonstrating that the in vitro acquisition of NK receptors by liver 28 or umbilical cord 29 T cells depends on IL-15.
Among inducible NCRs, NKp30 is clearly the most important for the antitumor activity of V␦1 ϩ T cells, based on the proportion of cells that express it (Figure 3D ), the higher enhancement in V␦1 ϩ T-cell cytotoxicity on NKp30 triggering ( Figure 5A) , and the significant reduction in leukemia cell killing on NKp30 blockade ( Figure 5B ). This notwithstanding, NKp44 (but not NKp46) is also functional in NCR ϩ V␦1 ϩ cells ( Figure 5A ), and appears to synergize with NKp30 for enhanced tumor targeting ( Figure 5B ). Of note, NKp30 engagement also augments the production of the key antitumor cytokine, interferon-␥, by NCR ϩ V␦1 ϩ cells (supplemental Figure 8 ).
Both NKp30 30 and NKp44 31 have been implicated in human NK cell recognition of virus-infected cells. Regarding tumors, antibody-mediated blocking experiments demonstrated important roles for these receptors in myeloma 32 and melanoma 33 cell targeting. Moreover, lack of NCR expression has been clinically correlated with poor survival in AML patients. 34 Interestingly, NKp30 and NKp44 are not encoded in the genome of murine strains (such as C57Bl/6 or Balb/c) widely used for laboratory experimentation. 35 On the other hand, the major V␥9V␦2 subset of human PBL, and its reactivity toward phosphoantigens, are also primate-specific. 6 These observations highlight the special functional characteristics of primate ␥␦ T cells; however, they also preclude the direct in vivo study of V␥9V␦2 or NKp30 ϩ V␦1 ϩ T cells in the mouse.
Another aspect that currently limits our understanding of NCR function in immunity is the poor definition of their physiologic ligands, most notably in the context of tumors. In fact, viral hemagglutinin was until recently the only well-established ligand for NKp44 36 and NKp46. 37 This notwithstanding, a novel B7 family member, B7-H6, was lately described to bind NKp30. 38 B7-H6 was not detected in normal human tissues but was expressed on human tumor cells, 38 in line with the recognition of "stressed self" by innate and innate-like lymphocytes. 14,39 However, we obtained no evidence for a role of B7-H6 in NCR ϩ V␦1 ϩ T-cell recognition of lymphoid leukemias; in fact, many of the NCR ϩ V␦1 ϩ T-cell targets expressed lower levels of B7-H6 than healthy control cells (supplemental Figure 9 ). Brandt et al had also previously noted that only 24 of 119 tumor cell lines tested expressed B7-H6. 38 Thus, future lines of research should clarify the repertoire of relevant ligands expressed by tumors susceptible to NKp30-mediated cytotoxicity. Moreover, although we have thus far concentrated on hematologic malignancies, upcoming work will address whether NKp30 ϩ V␦1 ϩ lymphocytes also possess enhanced cytotoxicity against solid tumors. Of note, V␦1 ϩ T cells have previously been shown to be cytolytic against melanoma and various carcinomas. 10 V␦1 ϩ T cells are the predominant ␥␦ T-cell subset during the fetal stage and early life, 40 when they are already able to respond to viral infection. 41 In adults, V␦1 ϩ T-cell expansions have been associated with CMV infection, 42 HIV-1 infection, 43 and tumors of either epithelial [7] [8] [9] or hematopoietic 44, 45 origin. An attractive prospect for adoptive transfer of activated V␦1 ϩ T cells is that they may display particularly good capacity for homing to tissues because, contrary to their circulating V␦2 ϩ counterparts, V␦1 ϩ cells are preferentially tissue-associated lymphocytes. 9 Interestingly, the Figure 1 ). Effect of blocking antibodies to NKp30, NKp44, NKp46 and TCR␥␦ (IMMU510) on tumor cell killing. (C) V␦1 ϩ PBLs were MACS-sorted after 20 days in PHA and IL-2 cultures for the assay described in (B), but using blocking antibodies to pan-TCR␥␦ (IMMU510 and B1.1), V␦1 ϩ TCR (TCS1), NKG2D or NKp30 and NKp44, or the depicted combinations. (ϩ) refers to control cultures without inhibitory antibodies; (-) refers to tumor cell cultures without V␦1 ϩ PBLs. Error bars represent SD (n ϭ 3, *P Ͻ .05; **P Ͻ .01; ***P Ͻ .001).
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For at IRCCS ISTITUTO CLINICO HUMANITAS on August 2, 2011. bloodjournal.hematologylibrary.org From abundance of V␦1 ϩ T cells at mucosal surfaces has been attributed to IL-15, which induces chromatin modifications that control TCR gene rearrangement. 46 Our key demonstration that NKp30 ϩ V␦1 ϩ cells are capable of targeting primary lymphoid leukemic cells is particularly relevant when taking into account that V␦1 ϩ T cells have been previously reported to be inefficient killers of primary leukemia or lymphoma cells, 44, 45 which has been attributed to their lack of expression of NKG2D ligands. 44 Interestingly, a recent study in which ␥␦ PBLs were activated with concanavalin A demonstrated higher killing ability of expanded V␦1 ϩ cells against B-CLL-derived cell lines. 47 It will be important to investigate whether this protocol also induces NKp30 expression on V␦1 ϩ cells. Thus, NKp30 ϩ V␦1 ϩ cells may provide a valuable layer of intervention against lymphoid malignancies.
A surprising finding that deserves further investigation is the preferential expansion of V␦1 ϩ T cells (among ␥␦ PBL) on PHA treatment in vitro ( Figure 3B ). Because this is not due to selective apoptosis of the dominant V␦2 ϩ counterparts (supplemental Figure  2) , it must derive from a proliferative advantage of V␦1 ϩ cells when receiving PHA-dependent TCR signals ( Figure 3A-B) . Provocatively, we have previously observed that V␦1 ϩ T cells express significantly higher levels of the CD27 receptor (compared with V␦2 ϩ cells) 48 ; CD27 costimulation enhances Bcl2a1 and Cyclin D2 expression and promotes ␥␦ T-cell survival and proliferation. 48 This study draws important novel (NCR-mediated) insight into the modus operandis of human ␥␦ T cells, and supports the emerging paradigm of ␥␦ T cells recognizing tumors via innate NK receptors rather than using the somatically rearranged TCR␥␦ (Figure 5B-C) . 6 This notwithstanding, the TCR has a major, albeit indirect, contribution to the antitumor function of NKp30 ϩ V␦1 ϩ cells. We showed that efficient induction of NKp30 expression on V␦1 ϩ cells depends on TCR stimulation; in its absence, ␥ c cytokines can only effect a very modest up-regulation of NKp30 expression ( Figure 4A-B) . Thus, TCR signals are upstream of Figure 1 ). Tumor cell death was evaluated by annexin-V staining (n ϭ 3, *P Ͻ .05). (E) Real-time PCR quantification of GzmB mRNA levels in freshly isolated, NKp30 (Ϫ) or NKp30 ϩ ␥␦ T cells. Error bars represent SD (n ϭ 3). (F-G) Representative plots (F) and data summary (G) for 5 primary B-cell chronic lymphocytic leukemia samples that were used in killing assays (as in Figure 1 ) with ␥␦ PBLs obtained from 6 distinct donors and activated with either HMB-PP and IL-2 or PHA and IL-2. NCR(-) ␥␦ PBL from HMB-PP and IL-2-activated cultures (gray bars) were compared with NCR(ϩ) ␥␦ PBL from PHA and IL-2-activated cultures (black bars). Error bars represent SD (n ϭ 6, *P Ͻ .05; **P Ͻ .01; ***P Ͻ .001).
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For at IRCCS ISTITUTO CLINICO HUMANITAS on August 2, 2011. bloodjournal.hematologylibrary.org From NKp30-mediated tumor cell recognition by NKp30 ϩ V␦1 ϩ lymphocytes. Interestingly, we have previously showed that, for V␦2 ϩ cells, TCR signals are essential for cell activation and cytotoxic differentiation, "upstream" of tumor cell recognition via NKG2D. 2 We therefore propose a "2-step" model for human ␥␦ T cells, in which they differentiate and are activated like prototypic T cells (ie, using the TCR), but rely essentially on NK receptors (such as NKG2D, NKp30 or DNAM-1) for tumor cell recognition. This is consistent with the critical role described by the Hayday and Girardi groups for NKG2D ligands in tumor surveillance by mouse ␥␦ T cells, 49, 50 and fits the general concept of NK receptors being the key molecular recognition determinants of "oncogenic stress." 39 From a clinical perspective, this study describes a protocol to induce NKp30 ex vivo, which should make it very feasible to expand and inject large numbers of cells into patients. Importantly, we were able to efficiently expand NKp30 ϩ V␦1 ϩ cells from B-CLL patients (supplemental Figure 10) . On reinfusion, the activation status of the cells could potentially be maintained via administration of low doses of IL-2, which appears to be sufficient to sustain NKp30 expression. Thus, after this first report describing the differentiation of NKp30 ϩ V␦1 ϩ lymphocytes, future work should evaluate their potential for adoptive cell immunotherapy of human cancer.
